Senolytic drugs

Senolytics research shows Longevity progress

Senolytic research in humans may be in its infancy, but there is reason for cautious optimism. Last week we reported on biotech company UNITY's decision...

Elysium publishes positive results from two studies for Basis

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction. In December 2019, Elysium announced a $40m Series...

Taking NAD+ to the next level

Nuchido’s systems pharmacology approach yields NAD+ supplement that claims to boost levels by 242%!    A new player in the NAD+ supplement market has arrived...

UNITY cuts lead program after clinical trial fail

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint. Senolytic therapy developer UNITY...

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies. Yesterday we published the first part of our interview with Greg Bailey, CEO of...

Juvenescence (1): from strength to strength in R&D and investment firepower

Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding. Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Exclusive interview: Professor Richard Faragher and cellular senescence

With senolytics driving investor interest in the Longevity sector, we speak to Professor Richard Faragher about resveratrol and the potential for rejuvenation of senescent...

Re-engineered immune cells are the life and soul of the CAR T

Chimeric cells prove effective senolytic agents in targeting aging. CAR T cells are being deployed against diseases caused by senescence with the hope that they...

“Avoid the use of DQ as a senolytic therapy”

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation today published its latest risk-benefit analysis, which explores...

Classifying aging as a disease – it’s all about the ‘how’

The hurdle of classifying aging as a disease, rather than an inevitability, has started to be overcome. Now Alex Zhavoronkov is pushing for us...

Longevity2020: Day 5 Recap

On Friday, the Longevity2020 online conference drew to a close, and the final day explored what people can be doing today to address their...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

Pathway to Longevity: get rid of zombie cells

Understanding the trigger for cellular senescence could help to forge new treatments for Longevity, stopping aging before it's started. Cellular senescence is a double-edged sword;...

Exclusive interview: A new generation of senolytic

When is a drug not a drug? When it's a NaNot. Interesting new technology that's already on its way through FDA and targeting $40m Series...

Senolytic breakthrough brings Longevity one giant leap closer

Mayo clinic researchers demonstrate senolytic drugs clearing senescent cells in humans for the first time. In a landmark trial, researchers from the Mayo clinic have...

Professor Lynne Cox talks senescence

Calling for better alignment between academia, spin outs and big pharma - we talk senolytic drug development with a key opinion leader Lynne Cox is...

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...